Research Analysts Issue Forecasts for Nkarta Q3 Earnings

Key Points

• HC Wainwright analysts have revised down Nkarta's Q3 2025 earnings per share estimate to ($0.31), lower than the previous expectation of ($0.26).
• Nkarta's last quarterly earnings report showed an actual EPS of ($0.31), which was better than the consensus estimate of ($0.37).
• Analyst ratings for Nkarta include one "hold," five "buy," and one "strong buy," with a consensus price target of $13.60.

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities research analysts at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for Nkarta in a research note issued on Wednesday, August 13th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.31) per share for the quarter, down from their previous estimate of ($0.26). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta's Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($2.00) EPS, FY2028 earnings at ($1.37) EPS and FY2029 earnings at ($0.88) EPS.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.06.

Several other brokerages also recently weighed in on NKTX. William Blair restated a "market perform" rating on shares of Nkarta in a research report on Thursday, May 15th. Wall Street Zen upgraded shares of Nkarta from a "sell" rating to a "hold" rating in a research report on Saturday. Mizuho reduced their price objective on shares of Nkarta from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Tuesday, June 10th. Stifel Nicolaus reduced their price objective on shares of Nkarta from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Finally, Needham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Nkarta in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, Nkarta presently has a consensus rating of "Buy" and a consensus target price of $13.60.

Nkarta Stock Down 1.1%

NASDAQ NKTX traded down $0.0250 on Friday, reaching $2.2750. The stock had a trading volume of 203,764 shares, compared to its average volume of 949,979. Nkarta has a 12-month low of $1.31 and a 12-month high of $6.63. The firm has a market capitalization of $161.58 million, a price-to-earnings ratio of -1.54 and a beta of 0.72. The stock has a fifty day moving average price of $1.95 and a two-hundred day moving average price of $1.89.

Institutional Investors Weigh In On Nkarta

Several institutional investors have recently made changes to their positions in the stock. Invesco Ltd. purchased a new position in shares of Nkarta in the fourth quarter valued at $30,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Nkarta in the 1st quarter worth about $32,000. ProShare Advisors LLC purchased a new stake in shares of Nkarta in the 4th quarter worth about $45,000. Savant Capital LLC purchased a new stake in shares of Nkarta in the 2nd quarter worth about $36,000. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Nkarta by 41.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company's stock worth $60,000 after buying an additional 7,030 shares in the last quarter. 80.54% of the stock is currently owned by hedge funds and other institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.